Biotechnology Common Tools Presentation on Shared Facilities Turin

Biotechnology Common Tools Presentation on Shared Facilities Turin, 19 th February 2010 Service and Support for Biotechnology in Berlin-Brandenburg

Agenda 1. Regional Sharing: Opportunities and restraints 2. Sharing on Campus Berlin-Buch: Research-Clinics-Biotech 3. Example of sharing practice: FMP Screening Unit

Opportunities for sharing in Berlin. Brandenburg Potential sharing Industry/SMEs No incubator offering space, money and know how Space (Bio Parks) Large-scale facilities Some but difficult cooperation; fee for service Ethical issues? Biomaterials Animal facilities Know-how Science Little cooperation; own equipment Almost no sharing of experts between companies (except for IT)

Regional Biotechnology Parks Bio. Technologie. Zentrum Hennigsdorf Campus Berlin-Buch Berlin Adlershof berlinbiotechpark Potsdam Biotech Campus Biotechnologiepark Luckenwalde

Identified (largescale) Facilities Name E 1 FEM Animal Facilities E 2 Synchroton BESSY II storage ring E 3 Centre for Biomaterial Development E 4 Clinical research unit of the Charité Research Organisation (CRO) E 5 Competence Center for Clinical Studies E 6 Experimental and Clinical research Center (ECRC) E 7 FMP screening Unit E 8 Green house facilities – Potsdam University E 9 Max-Planck-Institute –screening of RNA E 10 Platform for transnational research E 11 Ultra structure network

Agenda 1. Regional Sharing: Opportunities and restraints 2. Sharing on Campus Berlin-Buch: Research-Clinics-Biotech 3. Example of sharing practice: FMP Screening Unit

Campus Berlin-Buch § A modern science, health and biotechnology park with a clear focus on biomedicine and 2, 200 employees on 32 hectares § Unique environment for scientific exchange and research collaboration, facilitated by the close physical proximity of - research institutes - clinics - biotechnology companies § Major areas of activity include - study of the molecular causes of cancer cardiovascular and neurodegenerative diseases interdisciplinary basic research to develop new drugs patient-oriented clinical research commercial realization of biomedical insights § Investments of more than 200 million euros from the federal government, state government and the EU Innovative location with an attractive infrastructure and international flair

Concept ü High quality of living and working - closeness of the institutions to each other setting in a beautiful park landscape communicative places to eat, guesthouses, - kindergarten, research library synergy between science and art with sculpture park, exhibitions and a museum ü Events „Long Night of the Sciences“ - In June welcomes thousands of visitors annually - gives insight into the biosciences and medicine in an entertaining way through participatory courses, lab tours, "science comedy" and information booths ü Health Region - fast connection to Berlin‘s cultural life direct proximity to the lakes and forests provides numerous opportunities for leisure and recreation ü Communication & Information Max Delbrück Communications Center - one of the most modern congress centers in Berlin - serves as an international meeting place for researchers and physicians as well as an arena for active social discourse Campus. Info. Center - Located in the same historic building as the Life Science Learning Lab - popular with visitors and guests of the Campus as a place to meet and obtain information

Structure and on-site facilities Basic Research Institutes Clinical Research Institutes Maximum-care clinics Biotech. Park § § Max Delbrück Center for Molecular Medicine (MDC) Leibniz Institute for Molecular Pharmacology (FMP) Robert Rössle Clinic for Tumor Diseases (RRK) Franz Volhard Clinic for Cardiovascular Deseases (FVK) § § HELIOS Clinic Berlin-Buch Evangelische Lungenklinik Berlin (ELK) Rheuma Clinic Berlin-Buch All organized as private-enterprise entities § § Approximately 40 companies in 2009 Amongst others Silence Therapeutics, Glycotope, Ima. Genes, Invitek, Bavarian Nordic Outstanding innovation and growth potential through value-creating synergies

Research Institutes: MDC & FMP Structure Research objectives Methods Cooperations - One of 15 institutions of the Hermann von Helmholtz Association of German Research Centers (HGF) - Along with seven additional Berlin Leibniz Institutes it is administratively integrated into the Berlin Research Association - Undertakes modern biomedical and clinical - Main research areas are the elucidation of the research to develop scientifically-based methods structure, function and the interactions of of diagnosis, therapy and prevention proteins as well as the identification of small molecules (agents) - Scientists utilize molecular-biological and gene- - Makes scientific contributions in the first technological methods in order to analyze preliminary stages of drug development by complex diseases bringing together pharmacological basic research and the development of new drugs - Close cooperation with two specialist clinics - Many cooperation agreements with national (Robert Rössle Clinic for Tumor Diseases and the and international research institutes and with Franz Volhard Clinic for Cardiovascular Diseases)industry - Closely affiliated with the universities in Berlin due to five joint chairs, participation in teaching and diverse cooperations, e. g. within the scope of association research projects

Biotech Park Infrastructure § § § Approximately 26, 000 m² of sector-specific lab and office space is available to founders and companies under attractive conditions Additional sites for building on the Campus offer options for development over the middle and long term A tradition of excellence in molecular medical basic research and clinical research as well outstanding maximum care for patients make the Biotech. Park Berlin an ideal environment The creative atmosphere of the Campus promotes know-how exchange, technology transfer and joint projects Managed by BBB Managment Gmb. H Campus Berlin-Buch being responsible for coordinating the development of the entire site Companies § § At present approximately 47 biotechnology companies are located on the Campus with a total of 750 employees The spectrum of business fields includes - medical-technical products molecular diagnostics and therapies preclinical pharmacological and pharmacogenomics tests RNA technologies the search for pharma-relevant target molecules production and testing of drugs under the specifications of (GMP) analysis and synthesis of biomolecules

Proximity of facilities HELIOS Genomhaus (FMP & MDC) Biotech. Park MDC FMP

Agenda 1. Regional Sharing: Opportunities and restraints 2. Sharing on Campus Berlin-Buch: Research-Clinics-Biotech 3. Example of sharing practice: FMP Screening Unit

The Leibniz Institute for Molecular Pharmacology (FMP) Facts & figures § § 258 staff (08/08) 163 research scientists Budget 2008: 19 Mio Euro 5. 8 Mio Euro external funding (total in 2008) Research sections & focus § § Sections: Chemical Biology, Structural Biology, Signal Transduction/ Molecular Genetics Focus: - Structure and function of proteins New approaches to modulating protein function Identification of small molecules as chemical, diagnostic and therapeutic tools Identification of biological macromolecules as drug targets Mission § § Scientific Mission: - 40. 000 currently available drugs act through 324 structures (proteins) Up to 10. 000 structures are considered drug targets (proteins) Goal: broaden the basis of drug therapy! Organisational Mission: - Improve conditions for drug-related research and drug development by promoting interdisciplinary projects that combine chemical biological approaches (Chemical Biology) establishing drug discovery and development networks (public-private partnerships, national and international scale)

Screening at the FMP Screening Unit Open Access HTS Screening Robot Automatic Microscope § Projects on not (yet) validated targets § Development of chemical toos for the investigation of § protein functions, diagnostic substances and drugs Open platform for academic partners and SME

Featured technologies of screening unit in silico screening online database Process Automation Screening Unit Open Access HTS compound libraries unique technologies Lab. Chip Automated microscopes

Sharing of screening facility Open Access Screening Platform (> 80 projects since 2004) Yale University, Craig Crews University of Oxford, S. Knapp MRC Cambridge, E. Gherardi & T. Blundel University of Glasgow, E. Munroe Biotechnology Center Oslo, Kjetil Tasken University of Oslo, S. Strauss Karolynska Institute, S. Strömblad University Göteborg, S. Trybala Vanderbilt University, M. Waterman UCSF, L. Podust EMBL-Hamburg, M. Willmanns MPI-Dortmund, C. Ottmann Max-Planck-Group Hamburg, E. Mandelkow Max-Planck-Group Hamburg, H. Bartunik ZMNH Hamburg, M. Schachner TU München, J. Ruland Universität Leipzig, M. Schäfer Universität Frankfurt, R. Stauber Universität Rostock, Thiesen Universitätsklinik Marburg, T. Gress Bayer Schering Pharma, A. Sommer NDDI (Novartis, Boston, G. Petrella) Wnt-antagonists: Metastasis

European screening activities EU-OPENSCREEN § § § A European Infrastructure of Open Screening Platforms for Chemical Biology A distributed infrastructure open for transnational access Will be used by researchers from universities and research institutes who have either only limited inhouse facilities or no access at all to such an infrastructure Will accelerate the generation of knowledge on the bioactivities of chemicals as well as on the responses of biological systems Unlike commercial screening platforms and pharmaceutical industry EU-OPENSCREEN will address non-validated targets

EU-OPENSCREEN network* Coordination Centre at FMP Berlin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) Sweden – Univ. Umeå Finland – FIMM Nordic EMBL Helsinki Poland – IMB, Lodz Hungary – Univ. Budapest Czech Rep. – Inst. Molecular Genetics Prague Austria – Ce. MM Wien Italy – CISI Milano Switzerland – Ecole Polytechn. Féd. Lausanne Spain – Barcelona Science Parc, Portugal – Univ. Lisbon France – Univ. Strasbourg Netherlands – NKI Amsterdam European Bioinformatics Institute (EBI) UK – Univ. Dundee, Univ. Cambridge Denmark – Univ. Copenhagen Norway – Univ. of Oslo Greece – BRFAA Athens 2 16 1 15 14 13 3 12 5 11 6 8 4 7 10 9 17 *Important remark: This list shows the current network, which is not necessarily identical with the institutions participating in the PP.

Contact Details Thank you for your attention! Wolfgang Korek Bio. TOP Berlin-Brandenburg Fasanenstraße 85 10623 Berlin Tel: + 49 30 3186 -2218 korek@biotop. de www. biotop. de